🇺🇸 Ketamine infusion in United States

11 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Respiratory Failure — 2 reports (18.18%)
  2. Abdominal Distension — 1 report (9.09%)
  3. Acidosis — 1 report (9.09%)
  4. Acute Kidney Injury — 1 report (9.09%)
  5. Blood Creatinine Increased — 1 report (9.09%)
  6. Cardiac Arrest — 1 report (9.09%)
  7. Drug Ineffective — 1 report (9.09%)
  8. General Physical Health Deterioration — 1 report (9.09%)
  9. Haemoglobin Decreased — 1 report (9.09%)
  10. Hypernatraemia — 1 report (9.09%)

Source database →

Ketamine infusion in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Ketamine infusion approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Ketamine infusion in United States?

Yale University is the originator. The local marketing authorisation holder may differ — check the official source linked above.